Momespray50 mcg

Momespray 50 mcg Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. It is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. It is also indicated for the treatment of nasal polyps in patients 18 years and older.

Nasal Steroid Preparations

Momespray 50 mcg monohydrate is a corticosteroid demonstrating antiinflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, and cytokines) involved in inflammation. Protein binding for Momespray 50 mcg was reported to be 98% to 99% in concentration range of 5 to 500 ng/mL.The effective plasma elimination half life of Momespray 50 mcg is 5.8 hours.

Allergic Rhinitis Adults and Children 12 Years of Age and Older: The recommended dose for prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal symptoms of perennial allergic rhinitis is two sprays (50 mcg of Momespray 50 mcg in each spray) in each nostril once daily (total daily dose of 100 mcg). In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Mometasone Nasal Spray, 50 mcg (200 mcg/day) isrecommended 2 to 4 weeks prior to the anticipated start of the pollen season. Children 2 to 11 Years of Age: The recommended dose fortreatment ofthe nasalsymptoms of seasonal and perennial allergic rhinitis is one spray (50 mcg of Momespray 50 mcg in each spray) in each nostril once daily (total daily dose of 100 mcg). Nasal Polyps Adults18 years of Age and Older: The recommended dose for nasal polyps is two sprays (50 mcg of Momespray 50 mcg in each spray) in each nostril twice daily (total daily dose of 400 mcg). A dose of two sprays (50 mcg of Momespray 50 mcg in each spray) in each nostril once daily (total daily dose of 200 mcg) is also effective in some patients.

There are no drug interactions of note with Momespray 50 mcg.

Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

Side effects are generally mild and included headache, viral infection, sore throat, nosebleeds, and coughing.

There are no adequate and well-controlled studies in pregnant women. Momespray 50 mcg, like other corticosteroids, should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. It is not known if Momespray 50 mcg is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be used when Mometasone is administered to nursing women.

While using nasal corticosteroids, caution is required in patients with active or dormant tuberculous infection, or in untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex.

There are no data available on the effects of acute or chronic overdosage with Mometasone. Because of low systemic bioavailability, and an absence of acute drugrelated systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.